Earnings call transcript Q1 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. Welcome to Eyenovia First Quarter 2023 Earnings Call. [Operator Instructions]. Please note, this conference is being recorded. I will now turn the conference over to John Gandolfo, Chief Financial Officer. you. Thank

begin. may You

John Gandolfo

afternoon, Call to me and Michael Bren Eyenovia's Good XXXX today First Earnings CEO, Kern. COO, and Conference Audio Rowe; and you. Eyenovia's welcome Quarter are Thank Webcast. With

filed press a most ended ended Form today's the XX-Q report as months XXXX. with press issued we as XX, will XX, afternoon, release financial XXXX, as the as March to results everyone well encourage May quarter recently on well tomorrow, for March XX, XX-K. announcing which We release filed the X for read be SEC quarterly This Eyenovia's XXXX, our

Company's at annual www.eyenovia.com. report and press also release available website on our are

reference. will which have webcast product In the archived and of company's Please addition, be candidates, on some receive website to future be note call, today's discussing conference this that is investigational we being approval. FDA to will yet for call there

implied information those to covered and Securities harbor the call, note on business. call statements Form results be that also in Eyenovia's described Reform management associated our Act. report forward-looking materially stated in annual risks is Litigation a company's are by of on These XX-K. risks, certain provisions that We with statements. due caution will today during the subject Please could Actual forward-looking statements listeners are safe the discussed the the which from uncertainties forward-looking making to under or of these differ number more detail Private

Eyenovia call, forward-looking date circumstances reflect obligation revise may the conference applicable or of as XX, this securities accurate required by broadcast, of as no only contains law. after this the to that XXXX. of information any live events statements be conference is update This date except May or to call time-sensitive undertakes

to Michael? Executive the said, call Eyenovia's that like I'd Michael to Officer. Rowe, With over turn Chief

Michael Rowe

and our update start and our Conference John, recent Thank MicroLine. First welcome, will an follow for update our and progress. Financial readiness fits I XXXX update that Chief our within on MydCombi, provide of Kern, you, with how FDA commercial overall Officer, established Call. of Operating approval Results an then strategy to manufacturing will Bren with approval everyone, Quarter our

then over and CFO, will who Gandolfo, turn with review Arctic well partnerships John financials to + as our We things Lomb as our Vision. the will Bausch and

your We for questions. will then the open call

the and year, stated of more first our we During progress first this FDA of made product, by on all punctuated have recently, significant approval our of quarter goals, MydCombi.

MicroLine have the FDA, clear We also path a feedback we forward that and for encouraging received from believe very our Presbyopia program.

manufacturing, activities In quarter later this terms have we'll ramping clinical next with year. our we GenX online our batches of being Optejet are Reno facility produced up and

the that come, pave Finally, our partnership as with way others expect leverage well that we technology. as Optejet for will additional our ophthalmic to Formosa

I'll achievement. begin highlighting by the call our most recent

first approval is partnered additional U.S. days programs. of importance Optejet for thalamic short-term phenylephrine, Just delivered we where few is proprietary of in the in future The our the this the and the approved indications. This as desired. our of sets by inducing formulation FDA Optejet I received development approval. using the overstate well is precedent device. foundational and, company as for of product approval to our our of mydriasis the pipeline diagnostic fixed-dose first this in dispensing ago, approved conditions dilation and cannot other development tropicamide Optejet high-value and a also procedures combination importantly, And our tropicamide pupil FDA a for microdose is the of MydCombi, combination therapies to

company also important a for our just development marks indications that Optejet. this grateful ophthalmic provides external can the validation MydCombi the technology first their a crucial approval through of transition utilize of management to many and in dedication to approval of The this is FDA's the Eyenovia our organization. advancing formal from colleagues program is milestone. commercial The all Eyenovia team of extremely of The

have to and can she get volume One numerous from and dilate include the technicians. right her that optometry as she inbound in we the patients this e-mails for when that didn't office tilt flow, lower room, modify heads course, she see horizontal the their calls the back. they asking doctor very ophthalmology We, Since said and have plans could and both, doctors have offices reasons to wanting them waiting use of of the so delivery, received MydCombi. Monday, ease exposure, product drug The for encouraging.

summer to several plan optometry of ophthalmology targeted and as to We introduce process. our launch MydCombi key this offices part later

to like to need would have we online. as in production our much capabilities, some out more be we full capacity. cost XXXX, there are manufacturing bring and Reno efficient early which tomorrow, our at City As facilities internal we to By expect Redwood time

launch find our mydcombi.com. track and hear out the MydCombi doctors about about can going website by patients you saying of the and all to and what customers more now, progress are and product ultimately For soon

proprietary I'll we the in near improvement for based presbyopia. on-demand now temporary associated vision our parking developing MicroLine, topical pilot are turn to with that therapeutic candidate

vision. of United the you'll market ages representing will between otherwise people As cash million XX, States XX never and pay wear a presbyopia and for resources the XX the eye alone This the in hardening lens is recall, have an the is product. causing of glasses over near age-related blurred addressable

the could a research Our proprietary this alone. U.S. be market in market multibillion-dollar annual suggests,

Application MicroLine for cartridge feedback being registration in-home of more delineating our GenX smaller half And machinery contracted build has and the to XXXX batches a and our validated NDA Redwood fill after GenX the Optejet our first device, the in of received is with and designed The in we New being use. been optimized installed clinical NDA. the facility. satisfying anticipate running City FDA use recently for from advanced partners. needs forward program which this path clear is for Drug a We towards or

stability months data The NDA. product before FDA requires final packaged the filing the real-time on XX of

to intend batches. approximately months those after we we So XX run file

During those sitting XX months, not waiting. will however, we be and

and including be the usability pre-NDA measuring of Optejet commercialization of activities, clinical GenX will human in for demonstrate factors conducting other used NDA device the system. patient support as work This well to support to critical will preference We upcoming as and of the the the work population target be product. the both, MicroLine

The many they products model business portion conducted. And fit also and potentially for a of may from where and of they in features to device options. features research using those fit a paradigm As the their easier, practice make be so include lenses product highly retail spray as drug optometrists. an of with eye-drop it unique The ophthalmic have our part items feature well on tolerability. could the as to MicroLine attractiveness doctors presbyopia has improving itself technology better into device, supporting offerings. that unique presbyopic in a may MicroLine market contact patients. believe have Many MicroLine of the and Optejet we that starter apart other set preservative may as desired sell exposure been and pointed may their the we such able of of skins, while kits eyeglasses, as device lowering has number

market for the surveyed existing was optometrists MicroLine compared was in overall X We as in MicroLine doctors potential that terms doctors remaining optometrists' What could the was These drops MicroLine pharmaceutical of the recently needs. with rated estimated X/X presbyopia conducted capture the and eye that much or found research the the market where XXXX. X with on by #X of drops the meeting may eye XXX other their presbyopia we patients' competing as market. of that the with be X/X market,

Should patients approved, other from the volume, design, its a doctors with and of eye one only ultimately, and or be and we Optejet, lower MicroLine, will the be MicroLine drug product, number different believe that the drops distinguishes ease-of-use choosing spray.

a very were with We that collaboration platform potential nanoparticle ophthalmic the to to agreement activities. This excited Formosa's Pharmaceuticals. employ development development topical with February the of partnering formulation Optejet our for APMT therapeutics to combine device. seeks Optejet announce Formosa agreement our new Taiwan-based unique in Turning

and and improves homogenous active that from solubility delivery pharmaceutical APMT allowing platform existing benefit using innovative ingredients, expand Optejet. drugs could proprietary may Formosa's with future the of formulations our universe bioavailability more that

We key serve benefit own believe and ophthalmic part of to Co-development model large new and may addressing a discussions their eye. our with of development unmet advance our open potential strategy. and Optejet a may from Formosa We're within with potential programs as market dry as expansion mid- pipeline this, for that growth and such partners long-term partnerships are up indications will indications this needs with as glaucoma large for such continuing agreement future partnerships.

from results over with Hamrah, Optejet data are a the drops. in to of In Tufts conducted January, expression a body after administered superior appears study Center. Chairman of standard continuing Medical announced We Dr. of Ophthalmology standard we process. and study a latanoprost, Optejet positive This administered demonstrating build conventional cytokines Optejet eye at and glaucoma technology research via to Pedram Interim collaboration eyedrops. reducing with the early the versus large gene BAK preserved the of protein In chemokines inflammatory evaluated by these treatment findings, and medication with eyedrops benefits

of These found Ophthalmology therapeutic for presented can the and drugs in and be Association a results Optejet excess less using also Vision conventional with preservatives achieve were Meeting dose to The harmful month. last drops. latanoprost those to achieved significantly that Annual was at exposure Research

the turn to over our Kern, Officer, for call update. Chief like Bren Bren? I'd to point, this our At Operating manufacturing

Bren Kern

with approval the we've requests optimizing Thank align during in the hand, period. processes order our of finalize for being we working FDA With to Material and commercial our are launch. you, finalized, been preparations are Michael. MydCombi made upcoming by plans FDA MydCombi suppliers review to with

+ our delivered Vision, clinical Our Arctic Lomb supplies Redwood being facility, regularly. along partners, Bausch City to support continue manufacturers, our and contract with clinical with

the the streams the platform. progress Redwood of high-capacity, qualifying finish automated significant and the has progress to dispenser fill line, GenX City and made in to device. support instilled confidence support demand our a GenX has Additionally, finish facility which our would design for initiate line anticipated fill This

be half XXXX, the This occurring state-of-the-art installed system qualifications second in additional of should thereafter. with

significant continues Reno base our facility taken establishing in Recall, earnings was staff facility last progress office Reno These our ongoing. have construction occupancy. has we been and and manufacturing. call, Additionally, on completed, the injector our now to noted activities make

tools by as identification engineering through am Research. the and of dispenser we I over our of and products. April, amount months. Production rapidly we of array have and Eyenovia's Brambilla equipment installation activities already genuinely and arriving, capabilities be the about thereafter. joined drug increased increasing the of hires, announced engineering excited Vice quarter, his of which qualification we our addition made Enrico in President will significant Enrico leveraging us and is efficiencies, new are progress few across an last leveraged Product expertise Last will and follow

daily a is to of MydCombi on increasing our a drug technology demonstrated are viable successfully basis. And dispense capabilities platform ophthalmic the application. operations Our approval has solution topical

I'd to Financial a to provide now Gandolfo, update. Chief turn Officer, the to like over call financial John John? our

John Gandolfo

Bren. Thanks,

quarter first approximately $X.XX for share XXXX, compared to net per the or million the loss quarter XXXX. of of For per or $X.X was approximately first $X.X of share a $X.XX net loss million

development XXXX, XX%. a decrease million first $X.X of expenses This the approximately and for same million $X.X for of to approximately quarter totaled in Research compares the approximately XXXX. period

a For general of compared approximately first the administrative XX.X%. first million approximately of $X.X quarter expenses million decrease approximately for XXXX, with $X.X and the were XXXX, quarter of

XXXX. first quarter of in operating This of expenses decrease million to $X.X approximately for were XX%. million total expenses XXXX compared the approximately $X.X a represents for same operating the Total period of

cash March December $XX.X XX, approximately million of to XXXX. company's of was $XX.X as XXXX, compared million As XX, balance

In of upon credit on capital based Avenue the through additional ability million July facility XXXX, the approval to MydCombi. down $X an addition, has company its the recent draw XX,

a future Licensing to a the capital. current an nondilutive and complete And major source of source part our programs strategy agreements are as additional important company. of potential revenues of for is

half million reimbursement of addition the from of a I product I we $X above, Vision XXXX. balance to XX, of expect noted of cash our approximately development Arctic from expenses approximately second In payment $XXX,XXX the license a partners receivable in for March have as and XXXX,

the all no to to South update a It with will FDA-approved Vision our studies progression brief call for myopia Before our in with this U.S. Health for existing more. There Canada, on with China MicroPine formulation been for in and currently the programs we products and of in Bausch a MicroPine questions, of X or has open conclude and I proprietary pediatric clinical licensing reduction by Korea. atropine a shown myopia XX% therapies progression. indication. slow is drug are Arctic

lenses is related clinical are as this vision were and result multifocal costs part with myopic + III Phase or Lomb, glasses retinopathy Bausch enrollment If partner, to planned. and prescribed that left in as children. our typically progressing untreated, to the CHAPERONE retinal to transferred this Recall loss. detachment, agreement can ongoing of contact Bifocal, trial myopic

covers Our covers MydCombi. agreement and with MicroPine, Arctic MicroLine as South Greater well and Vision Korea as China

those So Arctic programs licensing X in now territories. is Vision our current all of

MicroPine from in of for opportunity myopia myopia China. significant pediatric suffered in The represents of that Education nearly particular, a children estimates all XXXX. Chinese XX% in Ministry

Arctic in to agreement sales provides milestones. royalties Vision us with Our addition development

when approved, and a of for term. if our funding So could over the significant non-dilutive MicroPine company be source long

$XX as To and license additional our we potential reimbursable in million $XX date, as over fees, next million development approximately have in to net expenses the agreements earn license have license X generated milestones well and years. the an

well. can approved, are products earn Upon significant commercialization, sales royalties as our if Eyenovia

continuing Formosa Optejet to address assess can consideration to we additional significant expansion leverage believe technology we also in as Pipeline facilities. we manufacturing expansion pipeline was as potential unmet building opportunities to a our large agreement ophthalmic such as indications. the our new We continue needs are were

provides on can forward from candidate we of potentially FDA-approved tropicamide a key U.S. agreement Optejet. III today, Pharmaceuticals. co-development market presbyopia highlights that In we alone. with program received FDA in pleased phenylephrine annual a mydriasis, a and utilize with the multibillion-dollar a feedback first path to summarize a efficient combination date. received to continue of announced the approval and for Formosa To address our MydCombi, and be fixed-dose We our performance MicroLine FDA We the Phase product to the that conclusion, clear

in quarter. facility be second third in to our facility manufacturing California operational. Redwood City, is Nevada, on is in And Our track Reno, the operational

to licensing progressing with of body sales study well milestones continued research royalties, adverse our potential offer the regulatory therapy for Optejet, of with are potential that to common and within development our bypass by Arctic + effects Lomb Optejet the use. of opportunity collaboration line agreements the significant highlighted continue to with ophthalmic to as We chronic and as well Vision and meaningful associated Bausch results have possibly on the expand as years. X And shown from sight

call We now to would to Operator? That remarks. concludes our prepared questions. the like open up

Operator

Instructions]. [Operator

first from Our question with is Ladenburg Thalmann. Kaplan Matt

Matthew Kaplan

And week. That the MydCombi. of congratulations on terrific was this approval news earlier

Michael Rowe

Thanks, Matt.

Matthew Kaplan

should you move about but remarks, little a that mentioned the to later of about year your be rollout? in bit next thinking Can we and that this commercial you some And prepared talk how year? as we to

Michael Rowe

producing rather for equipment. watching this other in be much. summer. be I'll facility to this Yes, Reno take going be later We're The manufacturing. that more that. lasers ovens our Thank here a out now, going to us to in And is you, installing that right actually is using it for and contract them or a our cost I'm efficient and much much Matt, rollout. own of on reason Reno, It's very staged rolling targeted than

a real have year in for rollout later year towards our we next offices push the of product running. this facility and going the key some production will summer. to going end out targeted come validated the But into we're have here this So MydCombi fully to get when

for the So example, everything next be on I doctors of more get some it it this we'll as at names able and and very it, for year, mydcombi.com, look into to for key collecting building would hands the momentum turn then to it's year. get

Matthew Kaplan

going you work Great. about bit and a out? And how talk can pricing little that's to

Michael Rowe

Yes.

$XXX is cartridges. X for price So

patients. let's support roughly a cartridge about $XXX will Each So XX say, cartridge.

X about on on that's what are now, doctors the about $X.XX. per they're patient $X.XX. eye drops, look So spending spending Right a you basis, if

us the customers compare savings, have as convenience they it. the told against time a being to situation that for that them when for $X.XX see better it's increase, adopt and that overall patients, don't the So hurdle the but their they any

Matthew Kaplan

Okay. a Great. bit. And then shifting little gears just

some you more that forward mentioned feedback the from registration? give to path You that FDA some the the us NDA received program. you Can MicroLine your positive on details and on feedback

Michael Rowe

Right.

a So more that transition we It's portable, was slender dispenser. studies We for more VISION-X to And MydCombi for product. were be consumer-friendly, MicroLine more same to great it's the approved in perfect our the that in. it to and and and our fits which and GenX, therefore, want, conducted VISION-X which [indiscernible] dispenser is however, clinic. want with

the basically, FDA to It GenX we that we way MydCombi. right information. question was gave how medication? FDA we're same how to they similar the that our fact, in So now. device deliver the thing characteristics is do get having do approval how the for that from you GenX And validating The exactly given us doing by MydCombi have that. to the very the in did know involves And wonderful they

And for about, been people can human actually I using when also the have which other wanted demonstrate factors, it. because thing they use to is were the they device, mentioned us that looking we're confident just they very

study have that. a there's you with So to little do formal

to So tent none going batches Vision, pole is to Bausch and batches. make make have -- the we sooner have really, can't for Arctic in for sure the we time. clinical partners Lomb is studies because to make delay we that that at atropine our And in MicroPine need The the making big supply because can reason + we the they us. of ongoing is that registration those only at

Matthew Kaplan

those And can just timeline to registration detail you batches? the -- for

Michael Rowe

Yes.

registration next batches stability. we to early year those So real-time XX of then and plan very have months

soon off it get into we the the it as drop NDA we results, and As stability goes.

Matthew Kaplan

Great.

making on CHAPERONE you an MicroPine questions. Arctic the kind Phase in Bausch Lomb their us terms program III? of + the that progress programs, the Vision specifically, been final question Can And give then update of in Okay. and have --

Michael Rowe

the to later Vision which end year. publicly to study When said we to point. it's X going that of their the this is starting had study is soon device years that this are is year. -- they to Lomb them, end enrollment finish believe X that they + don't be the efficacy as do, Generation their Bausch with get by Arctic intending X So as years. I

I shorter think it's than Bausch's.

So same going at the these both roughly of probably are finish time. up to

Operator

Our from Matthew with is H.C. Caufield Wainright. next question

Matthew Caufield

okay? guys you me Can hear Great.

Michael Rowe

Yes, Matthew.

Matthew Caufield

the Major MydCombi congrats on Awesome. obviously. approval,

opportunity the the curious missing seemingly do the approval. prospects sentiment I'm team's curious could What overall? from MydCombi could for following MydCombi Optejet have further investors be misinterpreting you the the if negative the been I the or perspective then on So about on stock think -- internal sorry, tied launch? if financing -- prospectively you was could separately, if And just necessary to or

Michael Rowe

do John, head a as one it to a with you scratcher? is of want start bit that

John Gandolfo

Yes, sure.

So a financing an -- from question. it's overall good

Vision overall financing working down So opportunities, and licensing have I million from Avenue Capital as facility clinical multiple immediately. now. an on these as well $X as including, reimbursement of could financing from as and supplies or all pretty credit of alternatives, we're Arctic standpoint, partnership or milestones where we Bausch draw we partnership the mentioned, The for much

financing have in traditional also We mechanisms place.

the force. building sales be the not up In a financing of MydCombi terms will launch, we for

cash about there MydCombi different is -- than really operating operating much quarter, we last was So the we had don't an to million. burn for burn be of our where roughly cash $X.X really launch it expect

next we the our factored through cash going forward. our that have pretty have financing well quarter as of that into we quarter of year. confident we're with that as into in resources, draw could down, what terms the all cash cash the we current And projections. we're constantly third But So second of evaluating sufficient know we alternatives we funds

So I your question. hope answers that

Michael Rowe

because like like put along to the some product get is approval, to our I've other I'd be crazy they ourselves. with that they not that for add goals might our keep feeding sales you a companies and to resources something force if basically. the the they the to observed companies, fire. go like efficient. that and spending add I of other at else people And to history almost it companies XXX-person We looking can and together overcommit not get or add and here Matthew, there start we're is as work. can being -- Yes. at look And think And spend grows, philosophy extremely going seen we that I've

spend, concerned be the may this approval people huge going commercial in the with that be to case. So be that's not increase to there's going that

Operator

Investor. Our next from question Private is Jason McDonald,

Jason McDonald

Yes.

really bigger When Just Michael. your one. where mean, in-house, Kind a to of there, as really your term? curious being I'm opportunity? outsourcing talk organization, of a revenue heads opportunity see. long-term But have some about quick having of and that's and if products I outsourced, an team the the just does are you wait view at technology course, obviously, point last hybrid had some the you generated you the long think the

Michael Rowe

being and a Thank shareholder you, thank Jason, and with partner you us. for

If Let the talk the segments me there in market. give opportunity an many are glaucoma, glaucoma example. different in we about

You a could be a be blocker, you could beta prostaglandin, and so you could inhibitor ROCK on. be a

multiply So is with to actually opportunities the you by that companies wanted that those the this product. into of market with different different have look glaucoma drugs if would can in one number that partnering ourselves we go a to we way have segments, at

I as a have in Optejet your mean patients, are good So there. areas use the looking if that these question? it's impact out situations. can more some it's Does we we magnify for it's for doctors, we and and good can as this good you that we can get get ways shareholder that answer the at of for

Jason McDonald

Yes, makes sense. total

John Gandolfo

add can also. I on thing if Yes,

pretty of think type all opportunity where structure, partnership we much large portion we economics the think could a where opposed to straight-out more license think as upside. that As we it you're giving a the of retain the of about as I agreement up about a type really

distinction structurally, well. make important as So an think, that's to I

Jason McDonald

it go than of you comes not of fairly Michael, works intent see blazing, other. kind you maybe to the the guys Is is to to this When in keep saying, just kind what agile one follow-up on to and to -- long be And to Absolutely. term, proceeding the kind these better expenses, of the Like with uptake a products looking that guns small? that with are stay point. when sense? in how that careful you're you're

Michael Rowe

That it. is exactly

So MicroLine. look have we add can as And MicroLine maybe years might to see, we when XX but X more, incur get salespeople ready takes don't to that expense we we we from today. have will and now, launch off,

Operator

[Operator Instructions].

Our next RN [indiscernible] question is from with and Associates.

Unidentified Analyst

My brought financing nature. back Is the or that asked contemplating till say any safe safe to caller. the XXXX? sustain question future, secondary we is dilutive it offering was goes up the previous know all in not financing -- that it I by -- to anything maybe possibly you're in say Is over to not financing near dilutive

John Gandolfo

is safe Well, doing I financing there. think main do we of We fashion whenever the we're you all we're that that the will I opportunities focus are least about tell in to out say think -- the evaluating that company, possible. dilutive certainly our it's what to is it

from other have term some will cash Capital the be a do over But in-depth do Avenue that short I So we we well analysis. facility available receivables mentioned, as in. as full as coming

no. I comes of to to So when tell do financing. want optionality have to say don't want say I that you a lot our I will don't we it yes, But

Unidentified Analyst

made secondary decision that to is right But dilutive pursue Okay. answer now, no correct? you've offerings, any

John Gandolfo

on capital a of have all and the But now, raise. right firm of evaluating decision there's we're with partners everything. opportunities that our we no been as financing absolute Well,

Unidentified Analyst

do I the on you that a do off beat if that, -- decide but you would think like And have dead to horse, -- don't into this you how would mean future, be? Okay. far

John Gandolfo

at we constantly. I alternatives haven't thought I that this in point evaluate will our really you about that time. tell

that anything at So I to point to this commit want in don't time. like

Unidentified Analyst

a of have stopping more overhang. is concern it's assurance, investors a no don't think see that is I if sure factor. hurdle -- bullish. or a company months. And a add the It that couple just there's And was to be waiting a in a that, factor. the would an for of you only there answer. to appreciate invest weeks secondary It's invest I knowing few want as company your that some your a to They come And anything a I everybody to to market to do in was right. It's All here lot overhang, have your but within no? or lot there I'm someone

John Gandolfo

No.

think I of that it, alternatives. our evaluating all that's we're constantly

Unidentified Analyst

you'd be what's to want But use I said so been from -- from this Okay. gather one last would probably far. the

Michael Rowe

-- me can and if I I wrong. -- correct Let if John, am me

Our develop strategy, as partnerships, had mentioned. And among John those some is bring other them. in things, with to would partnerships, associated money obviously,

like that, absolutely nondilutive preference. our are that things So are

it the what Robert, nondilutive, would So And X, for those. looking, to save for our on partnership very be you're a if is, the working then these dilutive preference would hard last we're option. close and or be and do John, that correct?

John Gandolfo

you at in is possible. fashion dilutive corner do us answer. the And least telling Yes. to, look all that things what Look, I trying we into think that -- you're I'm to an I think times,

Unidentified Analyst

understand. to first I you've or until the second you Yes, capital 'XX. And that said, last got glad you, I'm of as quarter

won't do a there this be for anyway. maybe while So need a to

John Gandolfo

you. Thank

Michael Rowe

Thanks.

Operator

Partners. Len Our with Doc Stoc next Yaffe question is from

Len Yaffe

you company development MydCombi be it welcome. you and all since success, a that [indiscernible] financing other and the as should shouldn't with on the It's have, applications a Michael, for that you've build that took to clear surprise over potential be Congrats and all CEO. out enjoyed the the

might and benefit medications, question you've they're both, given in in to prescribed discuss widely use convenience. having you which seems I clearly term that drops got separately ease Could showed is, of glaucoma, Optejet study, to topical that through be [indiscernible] My incentive are versus the of superiority both MydCombi believe, I the a be and people to would glaucoma, be the concerns interested, significant Eyenovia dollar there as markets that by that perhaps some expect the size of to the the of I where think would size be opportunities? would expressed but could not accrue caller. major such as ophthalmological the only Because overcome partnership last

Michael Rowe

you, Len. Thank

in we the glaucoma are and between somewhere who an example, are treated X patients X million United topical if million as glaucoma actually medications So use of there with States.

of you makes And between If expect therapy, without about is first-line which I up $XXX $XXX half in last branded I make at billion first-line and checked. to believe about it Any $X.X should glaucoma crazy. good look going that's time that, medication really

Historically, they genericized. were them before many of that made more than

partners the even Optejet who looking and benefits compliance of if you this we So opportunity the these number there of there potential adherence track are where to GenX and is And didn't in this of of the especially the are saying, can convey electronics patients. meaningful doctors, we to GenX. for benefits a us, the at because all could embedded that mention are out

it. So and what why basically and I we're package Optejet interested whole at, this in think looking that can the for medication bring glaucoma in a good looked And people [indiscernible] we're that's market. that's the

Operator

Our question a investor. Matthews [ph], private he's Alex from is next

Unidentified Analyst

about of my Congratulations talked I hadn't to want and out on I just great to the know ophthalmologist, he heard Optejet. product. achievement. about find marketing the the I

plan you get the do word to the how ophthalmologists the So all out country? around optometrists and

Michael Rowe

social next a through thank we have mean FDA. step through when various person now reaching because it I'm hear we things to go to will doctor meetings should the have takes like that And we my that Instagram. are approved, then of is would materials to LinkedIn you, e-mail, be get it Alex, the was That through or few approved about promotion weeks. media on he your and But glad marketing Well, didn't ahead been.

there. presence We have big a

be news able get the to will We out.

when all also offices, we some these placing the with highly will all to very they all talk of of to start it. visible begin see other, product each the they doctors, think I

that's he about your know she from now good. the would that will doctor that months fact the So I suspect X product. now, know or doesn't

Operator

We to closing for the Michael our I session. have back turn conference the end to question-and-answer over would reached of like comments.

Michael Rowe

very today, coming thank for for us much, on outlook Thank We you excitement concludes of the all operator. today's And our quarter. progress you significant joining our that call. we have conveyed and hope and

manufacturing program our And partners. of forward have progressing. our as approval updating approval on We presbyopia discussions MydCombi, with future the FDA to the And in with hand. potential first is you look well as progress we MicroLine

forward our look update to for second joining you later again quarter year. So we and this thank Bye-bye. us,

Operator

Thank today's you. conference. This does conclude

your this your participation. time. thank for You lines disconnect And at may you

Eyenovia (EYEN) 11 May 232023 Q1 Earnings call transcript